Crossmark

Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice

Crossref DOI link: https://doi.org/10.1038/gt.2016.36

Published Online: 2016-05-05

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chapdelaine, P

Gérard, C

Sanchez, N

Cherif, K

Rousseau, J

Ouellet, D L

Jauvin, D

Tremblay, J P
License Information

Text and Data Mining valid from 2016-05-05
More Information

Article History

Received: 22 November 2015

Revised: 9 March 2016

Accepted: 7 April 2016

First Online: 5 May 2016

Competing interests

: JPT is conducting research on gene therapy for Friedreich's ataxia under a research contract with Amorchem Inc. and a patent for such treatment has been applied for by his university. The other authors declare no conflict of interest.